Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping

By sjmartinez • May 3, 2025

Cavanaugh D, Holt SK, Dwyer E, Petersen E, Gore JL, Schade GR, Grivas P, Hsieh AC, Lee JK, Montgomery B, Schweizer MT, Yezefski T, Yu EY, Chen JJ, Liao JJ, Weg E, Zeng J, Jannat S, Berry DL, Master VA, Garcia JM, Reed MJ, Bentov I, Wright JL, Psutka SP. Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping. Urol Oncol. 2025 May 1:S1078-1439(25)00123-1. doi: 10.1016/j.urolonc.2025.03.025. Epub ahead of print. PMID: 40316478.

Tags: Hematology/Oncology, Publications

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu[...]

The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need to Know

Graham DM, Lofftus S, Azizi L, Berkowitz MJ, Teshome M. The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need[...]

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial

Wainberg ZA, Lee KW, Kim JG, Devoe C, Strickler JH, Baum J, Jia C, Kagey MH, Sirard CA, Stein A, Scott AJ, Pelster M, Moehler[...]